Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%
### Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%
Liver Cancer
#CARTTherapy #LiverCancer #SolidTumors
In recent years, China has made remarkable advances in CAR-T cell therapy, particularly demonstrating exceptional potential in liver cancer treatment. CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, involves genetically engineering a patient’s T-cells to enable precise recognition and elimination of cancer cells. This innovative therapy has shown impressive outcomes in treating hematologic cancers and is now showing promising potential in fighting more complex solid tumors—especially liver cancer.
### **A Ray of Hope with CAR-T Therapy Amid High Incidence of Liver Cancer**
Liver cancer ranks among the top three cancers worldwide and poses a significant health threat. The high incidence of liver cancer, largely related to chronic hepatitis B infection, is particularly evident in China, which accounts for 42.4% of global liver cancer cases, with an annual increase of 368,000 new cases. For many liver cancer patients, especially those with advanced-stage disease, traditional treatments offer limited effectiveness. CAR-T therapy, however, provides new hope. Recent studies indicate that the disease control rate of CAR-T therapy for advanced liver cancer patients in China has reached an impressive 78% to 91.3%, showcasing its powerful treatment potential.
### **Patient Stories: CAR-T Therapy as a Turning Point in Life**
One inspiring case is that of Mr. Zhang from China. Long troubled by chronic hepatitis, he was diagnosed with advanced liver cancer in 2016. Despite undergoing liver resection, the cancer recurred with multiple intrahepatic metastases, spreading to retroperitoneal lymph nodes and forming a tumor thrombus in the inferior vena cava. After multiple rounds of embolization and ablation, the tumor remained uncontrolled. Given the limited efficacy of traditional treatments, doctors recommended CAR-T therapy. Following CAR-T treatment, Mr. Zhang’s tumors completely disappeared, and he has remained tumor-free for over seven years without severe side effects. This case highlights both the efficacy of CAR-T therapy and its potential to offer hope.
Another patient, Mr. Li, also benefitted from CAR-T therapy. When other treatments proved ineffective, doctors developed a liver cancer-specific CAR-T “special force” of four billion cells for him. Upon injection of these modified CAR-T cells, Mr. Li’s alpha-fetoprotein levels dropped rapidly, and the tumor gradually shrank. In subsequent treatments, Mr. Li’s tumor disappeared entirely, and his condition has remained stable long-term. This success story further underscores CAR-T therapy’s impressive results in treating liver cancer.
### **Future Outlook: Challenges and Opportunities for CAR-T Therapy in China**
While CAR-T therapy has achieved notable successes, challenges remain. Compared to hematologic cancers, the environment for treating solid tumors is more complex, and enhancing the efficacy of CAR-T cells in solid tumors requires ongoing optimization. However, the promising research and clinical results instill confidence in CAR-T therapy’s future in liver cancer treatment. Chinese researchers are actively working to refine CAR-T cell therapy, explore combination treatment strategies, and foster international collaboration to benefit more patients.
In the future, CAR-T therapy in China is expected to become a powerful tool in liver cancer treatment, offering new hope to thousands of patients. With ongoing technological advancements and deepening clinical practice, CAR-T therapy in China will continue to advance cancer immunotherapy and provide new possibilities for the health of liver cancer patients.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #ChinaMedicalAdvances #CancerImmunotherapy #MedicalBreakthrough #CancerResearch #LiverCancerAwareness #AdvancedCancerTreatment #CancerSurvivors #BiotechInnovation #GeneTherapy #Oncology #MedicalInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%
Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%
Gastric Cancer
According to a report by People’s Daily on April 6, 2023, China has achieved another milestone in the CAR-T field. Recently, China Jiangxi Province successfully completed its first case of CAR-T cell therapy for solid tumors. This not only represents a significant breakthrough in new cancer treatment technologies in Jiangxi but also marks a major advancement in China’s CAR-T research and application.
China’s Jiangxi Achieves a Breakthrough in CAR-T Therapy for Solid Tumors
The patient, an advanced gastric cancer patient, had previously undergone chemotherapy combined with immune checkpoint inhibitor (ICI) treatment, but the disease was not well controlled. The tumor had widely metastasized to the abdominal cavity and multiple bones, accompanied by complications such as anorexia, abdominal distension, and severe recurrent reduction in blood cells, making the patient unable to tolerate chemotherapy.
With no other options, the patient received CAR-T cell reinfusion therapy on March 20, 2023, at the Oncology Center of The Second Affiliated Hospital of Nanchang University, with substantial support from the team at Peking University Cancer Hospital (Beijing Cancer Hospital). Fortunately, the patient has safely passed the peak period of cytokine release syndrome (CRS). Compared to before CAR-T treatment, tumor markers have decreased to normal levels, and the patient’s physical condition, mental state, and symptoms (such as abdominal distension and anorexia) have significantly improved. This marks a “zero breakthrough” for CAR-T cell therapy in solid tumors in Jiangxi Province of China, leaving a significant mark in the field of CAR-T research and application in China.
Peking University Cancer Hospital Showcases CT041 CAR-T at 2024 ASCO Conference with a Disease Control Rate of 96.1%
In addition to this fortunate case, the research team from Peking University Cancer Hospital showcased a domestically developed CAR-T product named “satri-cel” (development code CT041) at the recent 2024 American Society of Clinical Oncology (ASCO) conference. Satri-cel is a CAR-T cell therapy targeting Claudin18.2 (CLDN18.2) and is the only CLDN18.2 CAR-T cell therapy in the world approved for clinical trials (IND) in both China and the United States, targeting digestive tract tumors such as gastric cancer and pancreatic cancer.
The final results of the Phase 1 clinical trial (NCT03874897) were presented in an oral report at this conference. In patients with gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) treated with satri-cel monotherapy, the results showed a disease control rate (DCR) of 96.1% (49/51), an objective response rate (ORR) of 54.9% (28/51), a median overall survival (mOS) of 9.0 months, a median progression-free survival (mPFS) of 5.8 months, and a median duration of response (mDOR) of 6.4 months.
As early as May 2022, the team at Peking University Cancer Hospital had reported clinical cases of CT041 treating gastric cancer. A 57-year-old gastric cancer patient (Pt08), who had previously undergone three treatments, including PD-1 antibody, showed improvement after receiving CT041 CAR-T cell therapy. Visual inspection and CT scans indicated that the patient’s condition improved, with reduced umbilical tumor lesions, and the efficacy was still ongoing as of the date of the report.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #GastricCancer #LiverCancer #BrainTumor #PancreaticCancer #MedicalBreakthrough #Oncology #Jiangxi #ChinaBiotech #CancerResearch #ASCO2024 #PekingUniversityCancerHospital #InnovativeTherapy #MedicalAdvancements #HealthNews
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward
Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward
Liver cancer, CAR-T
CT011
On January 15, 2024, #CARsgen Pharmaceuticals announced that its autologous #CARTcell candidate product #CT011, targeting Glypican-3 (GPC3), has been approved for clinical use in China. It is intended for the treatment of GPC3-positive stage IIIa hepatocellular carcinoma patients at risk of recurrence after surgical resection.
Glypican-3 (GPC3)
Glypican-3 (GPC3)plays a crucial role in regulating cell growth and differentiation and is closely associated with the occurrence and progression of liver cancer. GPC3 is expressed in reproductive system tumors such as hepatocellular carcinoma, ovarian clear cell carcinoma, and yolk sac tumors. Its expression rate in hepatocellular carcinoma reaches 74.8%, while it is virtually absent in normal liver tissue, making it an ideal new target for #livercancer #CARTtherapy.
Promising Target
Due to its tumor specificity, GPC3 is considered a promising target for cancer immunotherapy. Higher expression of GPC3 in hepatocellular carcinoma is associated with poorer prognosis.
Frontiers in Immunology
In August 2022, a Chinese medical team published a long-term survival case report of treating advanced hepatocellular carcinoma with CT011 in the journal “#FrontiersinImmunology.” The study reported complete remission (#CR) and long-term survival in a patient with advanced hepatocellular carcinoma after receiving GPC3 CAR-T cell therapy in combination with the multi-target kinase inhibitor sorafenib.
Results showed good tolerance to CT011 combined with sorafenib treatment. The patient achieved partial remission (PR) from the third month onwards and attained complete remission at the 12th month after the first CT011 infusion. The tumor did not progress for over 36 months, maintaining complete remission status for over 24 months after the first infusion.
Cancer Communications
On October 12, 2023, CARsgen Pharmaceuticals announced the clinical efficacy of its independently developed CAR-T cell therapy targeting GPC3 in two patients with advanced hepatocellular carcinoma (HCC). The clinical trial results were published in “#CancerCommunications.” Both patients had inferior prognostic outcomes upon enrollment, with one having inferior vena cava tumor thrombus and the other having retroperitoneal lymph node metastasis.
In the clinical trial, one patient received local treatment for intrahepatic recurrent tumors and inferior vena cava tumor thrombus (microwave ablation and gamma knife) before receiving CAR-T cell therapy targeting GPC3. Six months later, AFP (alpha-fetoprotein) levels normalized, and imaging revealed no active tumors. The other patient underwent local treatment (microwave ablation and gamma knife) for controlling intrahepatic tumors, inferior vena cava tumor thrombus, and peritoneal lymph node metastases while receiving CAR-T cell therapy.
Encouragingly, both patients showed significant efficacy after combined local treatment and CAR-T cell infusion, maintaining tumor-free status during long-term follow-up, with both individuals being tumor-free for over 7 years. Throughout the follow-up period, both patients only received oral antiviral therapy for hepatitis B and did not undergo any other cancer treatment.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.
The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.🌞🌞
🥰Surviving Against the Odds: A Chinese Doctor’s Journey with Liver Tumor🥰
Zou began his career in 1989 and has dedicated 30 years as an obstetrician-gynecologist, tirelessly working on the frontline of clinical care.
⭐️”Prof.Shi mentioned this immunotherapy, an antibody treatment,” said Dr. Zou’s wife.⭐️
Unveiling Hope: Chinese CAR-T Cell Therapy Illuminating New Paths in Liver Cancer Treatment!
2020, over 19.3 million people were diagnosed with cancer worldwide, leading to almost 10 million fatalities. In China alone, the number of new cancer patients reached a staggering 4.57 million, accounting for 23.7% globally. Liver cancer, among the most prevalent malignant tumors in China, witnessed 410,000 new cases and 380,000 deaths, making up 45.3% and 47.1% of the global total, respectively [1]. However, since the 21st century began, significant strides have been made in liver cancer treatments, particularly in medication and localized therapies. Surgical procedures are no longer the sole option for long-term survival among liver cancer patients.
Immunotherapy has emerged as one of the most promising techniques for treating liver cancer, especially with advancements in tumor molecular biology. In 2013, “Science” magazine categorized immunotherapy as the fourth major cancer treatment, following surgery, chemotherapy, and radiation therapy, with cell therapy becoming a focal point of basic and clinical research in recent years.
In May 2020, Professor Zhai Bo’s team from Shanghai Jiao Tong University School of Medicine’s Renji Hospital, in collaboration with Shanghai Sci-Tech Biotechnology’s team led by Li Zonghai, published groundbreaking preliminary clinical research data on CAR-T cell therapy targeting the GPC3 gene for hepatocellular carcinoma in the “Clinical Cancer Research” journal. This breakthrough study brought unprecedented hope for CAR-T cell therapy in liver cancer treatment.
Even more inspiring, their publication in the “Cancer Communications” journal showcased follow-up results of two late-stage liver cancer patients who achieved long-term tumor-free survival after receiving CAR-T cell combined with local therapy [2]. These findings shed new light on the treatment prospects for liver cancer patients.
However, despite the potential therapeutic effects of liver cancer CAR-T cell therapy, it faces challenges and obstacles. Liver cancer’s heterogeneity, tumor microenvironment, and the safety of cell therapy remain crucial issues to address.
Presently, revolutionary changes are underway in the treatment models and concepts for liver cancer. However, integrating CAR-T cell therapy into actual liver cancer treatment requires further scientific exploration and clinical research. Researchers emphasize that only through comprehensive utilization of CAR-T cells in conjunction with other treatment modalities can its therapeutic potential be fully realized.
Professor Zhai Bo’s team is currently conducting various fundamental and clinical studies aimed at exploring additional possibilities for CAR-T cell therapy in solid tumors. These studies include phase I clinical research on EpCAM CAR-T cell combined with ablative therapy for gastrointestinal tumors, phase II clinical research on Claudin18.2 CAR-T cell therapy for gastrointestinal tumors, studies on the mechanism and prevention of OTOT toxicity, among others. These endeavors will provide more experimental data and support for the application of CAR-T cells in the treatment of solid tumors.
In conclusion, liver cancer CAR-T cell therapy signifies a significant breakthrough in the field of liver cancer treatment, offering new hope for patients. Despite the challenges to overcome, the outlook for this therapy is promising and holds the potential to bring a blessing to more patients in the future.
[References]
Zhaibo, Lizonghai etc.
“Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials.” 《Clinical Cancer Research》, 2020.
“Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.” 《Cancer Communications》, 2023.
#HealthTech#CancerResearch #Immunotherapy #CARTcell #LiverCancer #MedicalBreakthrough #ClinicalTrials #ScienceNews #HealthcareInnovation #ResearchBreakthrough #MedicalScience #CancerTherapy #CancerAwareness #InnovativeMedicine #ImmunotherapyTreatment #ScienceUpdates #HealthcareTechnology #BiomedicalResearch #ClinicalInnovation #CancerTreatment #MedicalAdvancements #ImmunologyResearch #HealthcareIndustry #ProfessionalHealthcare